Publication | Open Access
PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
50
Citations
0
References
2021
Year
Poseidon StudyOncologyMedicineClinical TrialsImmune Checkpoint InhibitorFirst-line TreatmentPharmacotherapyCancer TreatmentImmunotherapyPharmacologyPhase 3
No additional data available for this publication yet. Check back later!